Nasus Pharma Ltd. NSRX 深 沪
已收盘 01-30 16:00:00 美东时间
5.74
+0.150
+2.68%
华盛通- 最 高5.74
- 今 开5.74
- 成交量 2.63万股
- 最 低 5.74
- 昨 收 5.59
- 总市值 5200.21万
- 52周最高 9.9899
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 5.50
- 委 比 0.00%
- 总股本 905.96万
- 历史最高 9.9899
- 量 比 7.42
- 振 幅 0.00%
- 历史最低 5.50
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasus Pharma Announces Interim Results From Phase 2 Clinical Study Of NS002, Investigational Intranasal Epinephrine Powder Formulation For Treatment Of Anaphylaxis
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen®91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with
01-20 21:03
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma announced positive interim results from its Phase 2 study of NS002, an investigational intranasal epinephrine powder for anaphylaxis treatment. NS002 showed faster absorption, higher peak concentrations (Cmax: 655 pg/ml vs. 548 pg/ml) and earlier peak times (10.8 min vs. 15 min) compared to EpiPen®. 91% of participants achieved the 100 pg/ml threshold at 5 minutes with NS002 vs. 67% with EpiPen®. NS002 was well-tolerated with no seri...
01-20 13:00
Nasus Pharma CEO Issues 2025 Letter to Shareholders
Nasus Pharma Ltd. reported significant progress in 2025, including a $10 million IPO, collaboration with Aptar for NS002's clinical development, and Health Canada approval for Phase 2 trials. NS002, an intranasal epinephrine powder for anaphylaxis, showed promise in early trials with faster absorption. The company aims to advance NS002 toward commercialization, with key milestones including Phase 2 data readout, IND submission, and pivotal/pediat...
2025-12-22 13:00
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19
Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outperform rating and announces Price Target of $19.
2025-12-18 21:13
Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephrine Powder Formulation With Dosing Of First Patient To Treat Anaphylaxis
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today
2025-11-18 21:07
Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced
2025-11-06 21:09
Nasus Pharma Updates Corporate Presentation
Nasus Pharma Ltd. ( ($NSRX) ) has provided an update. On November 3, 2025, Nasu...
2025-11-03 21:25
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Nasus Pharma partners with Aptar to accelerate NS002 development, a needle-free intranasal epinephrine product for anaphylaxis. The collaboration provides proven Unit Dose System technology, regulatory support, and manufacturing capabilities, aiming to speed up FDA and EMA approvals while minimizing risks. NS002 leverages Nasus' proprietary powder-based intranasal technology for rapid drug delivery via the nasal cavity's vascular network, offerin...
2025-10-08 12:04
Nasus Pharma Ltd. Secures Additional Funding from IPO Over-Allotment
Nasus Pharma Ltd. ( ($NSRX) ) just unveiled an announcement. On September 30, 2...
2025-10-01 04:38
